Biochem/physiol Actions
Reversible: no
Product does not compete with ATP.
Target IC50: 11 nM against NF-κB transcriptional activation in Jurkat cells
Cell permeable: yes
Primary TargetNF-κB transcriptional activation
General description
A cell-permeable quinazoline compound that acts as a potent inhibitor of NF-κB transcriptional activation (IC50 = 11 nM in Jurkat cells) and LPS-induced TNF-α production (IC50 = 7 nM in murine splenocytes). Does not exhibit cellular cytotoxicity even at concentrations as high as 10 µM. Reported to exhibit anti-inflammatory effects on carregeenin-induced paw edema in rats.
A cell-permeable quinazoline compound that acts as a highly potent inhibitor of NF-κB transcriptional activation (IC50 = 11 nM in Jurkat cells) and LPS-induced TNF-α production (IC50 = 7 nM in murine splenocytes). Shown to exhibit anti-inflammatory effect on carrageenin-induced paw edema in rat. A 10 mM (1 mg/281 µl) solution of NF-κB Activation Inhibitor (Cat. No. 481407) in DMSO is also available.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Other Notes
Due to the nature of the Hazardous Materials in this shipment, additional shipping charges may be applied to your order. Certain sizes may be exempt from the additional hazardous materials shipping charges. Please contact your local sales office for more information regarding these charges.
Tobe, M., et al. 2003. Bioorg. Med. Chem.11, 383.
Packaging
Packaged under inert gas
1 mg in Plastic Bag(s)
Reconstitution
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Warning
Toxicity: Toxic (F)
This product has met the following criteria to qualify for the following awards: